Close Menu

NEW YORK ─ Oxford Immunotec's stock price was up 15 percent at the start of trading on Friday on a report that a consortium of private equity firms, KKR and Ampersand Capital Partners, has approached it with a $400 million acquisition offer.

KKR and Ampersand Capital have proposed acquiring Oxford Immunotec for around $15 per share in cash, Reuters said on Thursday, adding that the offer is preliminary and was submitted to Oxford Immunotec in the last few days.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.